Company: PETVW
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001493152-25-006783
Chunk: 42

Company: PetVivo Holdings, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
 cushion or shock-absorbing features to the joint and to provide joint lubricity).

28

Osteoarthritis,
a common inflammatory joint disease in both dogs and horses, is a chronic, progressive, degenerative joint disease that is caused by
a loss of synovial fluid and/or the deterioration of joint cartilage. Osteoarthritis affects approximately 14 million dogs and 1 million
horses in the $11 billion companion animal veterinary care and product sales market.

Despite
the market size, veterinary clinics and hospitals have very few treatments and/or drugs for use in treating osteoarthritis in dogs, horses,
and other pets. As there is no cure for osteoarthritis, current solutions treat symptoms, but do not manage the cause. The current treatment
for osteoarthritis in dogs generally consists of the use of nonsteroidal anti-inflammatory drugs (or “NSAIDs”) which are
approved to alleviate pain and inflammation but present the potential for side effects relating to gastrointestinal, kidney, and liver
damage and do not halt or slow joint degeneration. The Company offers an alternative to traditional treatments that only address the
symptoms of the affliction. Spryng™ with OsteoCushion™ technology addresses the affliction, loss of synovial fluid, and/or
the deterioration of joint cartilage, rather than treating just the symptoms and, to the best of our knowledge, has elicited minimal
adverse side effects in dogs and horses. Spryng™-treated dogs and horses have shown an increase in activity even after they no
longer are receiving pain medication or other treatments. Other treatments for osteoarthritis include steroid and/or hyaluronic acid
injections, which are used for treating pain, inflammation and/or joint lubrication, but can be slow acting and/or short lasting.

We
believe Spryng™ is an optimal solution to safely improve joint function in animals for several reasons:

    ●
    Spryng™ addresses
    the underlying problems which relate to deterioration of cartilage causing bones to contact each other and a lack of synovial fluid.
    Spryng™ provides a biocompatible lubricious cushion to the joint, which establishes a barrier between the bones, thereby protecting
    the remaining cartilage and bone.

    ●
    Spryng™ is easily
    administered with the standard intra-articular injection technique. Multiple joints can be treated simultaneously.

    ●
    Case studies indicate